Kardigan stock
KARDNASDAQKardigan, Inc., HealthcareISIN US4859251013
44Score 44 out of 100, Weak
Price and trend
85 / 100
Price history
−36% since 2026The chart shows daily closing prices since 18 Jun 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 45% below its 52-week high. Largest decline since 18 Jun 2026: 51% (June 2026 to October 2026).
Chart figures for advanced users
- SMA 50$15.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.12
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.63
- The lowest closing price of the last twelve months.
- Resistance$25.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Kardigan, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.26B, is number 173 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 44 out of 100 (Weak): rank 473 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $335.49M, financial debt $13.83M.Stability 69
Weaknesses
- Loss-makingLoss of $191.94M over the last 12 months.Fundamentals 10
- Negative free cash flowFree cash flow −$157.7M over the last 12 months.Fundamentals 10
Its standout strength is technical analysis, while profitability and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 46 to 44.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 3 Mar 2027in 110 days
- Last reported
- 12 Nov 2026EPS reported −$0.64 (expected −$0.78)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 9.9% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$5.140.0%
- Revenue
- $285.71K−42.9%
- Earnings per share
- −$3.68−9.9%
- Revenue
- $428.57K−42.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Not counted: 2 purchases under a fixed plan (compensation, savings plan or a pre-arranged Rule 10b5-1 trading plan).
- Hrtg Gpe, LlcPlan purchase
22 Jun 2026, Major holder
- Shares
- 3,125,000
- Price
- $16.00
- Value
- $50M
- ARCH Venture Partners XIII, LLC, Berns Paul LPlan purchase
22 Jun 2026, Board
- Shares
- 1,250,000
- Price
- $16.00
- Value
- $20M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Kardigan
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- COMPASS PathwaysCMPS $1.28B35
- IdorsiaIDIA.SW $1.28B35
- Nektar TherapeuticsNKTR $1.27B29
- GH ResearchGHRS $1.27B36
- Rapport TherapeuticsRAPP $1.24B33
- Alpha Tau MedicalDRTS $1.24B42
- SavaraSVRA $1.2B33
- MedinCellMEDCL.PA $1.16B47
ETFs that hold Kardigan
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.